The engineered antibodies targeting CTLA-4, Yervoy (ipilimumab), was approved by the FDA for the treatment of metastatic melanoma in 2011, which marked the first FDA approved ICI and started the rapid expansion of ICI for cancer immune therapy. The gene discussed is CTLA4; the disease is cancer.